Reckitt Benckiser wants out of pharma

Share this article:

Reckitt Benckiser is getting out of the pharmaceutical business. Bloomberg reports that the company plans to spin off the unit so the main company can focus solely on consumer health.

RB expects the split to wrap within the next 12 months, but has indicated it was open to selling the business if it could find a taker. Bloomberg notes that the addiction treatment Suboxone is the division's key drug. CEO Shaun Thaxter is expected to continue to run the unit post spin-off.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.